GT Biopharma, Inc.
GTBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,786 | $10,305 | $846,733 | $2,576,240 |
| - Cash | $3,951 | $1,079 | $5,672 | $8,968 |
| + Debt | $0 | $58 | $174 | $31 |
| Enterprise Value | $1,835 | $9,284 | $841,235 | $2,567,303 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$13,162 | $5,979 | -$20,965 | -$57,477 |
| % Margin | – | – | – | – |
| Net Income | -$13,162 | -$7,597 | -$20,884 | -$58,013 |
| % Margin | – | – | – | – |
| EPS Diluted | -6.94 | -5.64 | -0.66 | -2.06 |
| % Growth | -23% | -754.5% | 68% | – |
| Operating Cash Flow | -$12,904 | -$8,852 | -$15,217 | -$15,606 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$12,904 | -$8,852 | -$15,217 | -$15,606 |